Proteomic study of Jintiange capsule in the treatment of retinoic acid-induced osteoporosis rats

doi:10.12307/2023.823

Abstract

Abstract: BACKGROUND: The therapeutic effect of Jintiange capsule on primary osteoporosis has been confirmed by clinical research evidence and recommended by clinical application guidelines, but its effects and targets against secondary osteoporosis remain unclear.
OBJECTIVE: To explore the therapeutic target and mechanism of Jintiange capsule in the treatment of secondary osteoporosis.
METHODS: Twenty-four female Sprague-Dawley rats were randomly divided into four groups (n=6 per group): blank group (with no treatment), model group, Jintiange capsule group, and positive control group. Animal models of osteoporosis were prepared in the latter three groups by intragastric administration of retinoic acid. Fourteen days after modeling, the model group was intragastrically given normal saline, while the Jintiange capsule and positive control groups were given Jintiange capsule and alendronate sodium, respectively, for 14 days. After treatment, the femurs were taken for micro-CT scanning and tandem mass tags quantitative proteomics. Bioinformatics was used to analyze the function, signal pathway and protein interaction of the differential proteins and to screen the core proteins.
RESULTS AND CONCLUSION: Compared with the blank group, bone volume fraction, trabecular thickness and trabecular number of the femur were significantly decreased (P < 0.05) and trabecular separation was significantly increased (P < 0.05) in the model group. Compared with the model group, bone volume fraction, trabecular thickness and trabecular number of the femur were increased (P < 0.05) and trabecular separation was decreased (P < 0.05) in the positive control and Jintiange capsule groups. A total of 2 749 differential proteins were screened between the model group and the blank group, involved in multiple biological processes such as ATP metabolism, hypoxia response, and cellular iron homeostasis as well as signal pathways such as ferroptosis, hypoxia-inducible factor 1 signal pathway, and fatty acid metabolism. A total of 773 differential proteins were screened between Jintiange capsule group and model group, involved in biological processes such as ossification, hydrogen peroxide biosynthesis, and hypoxia reaction as well as signal pathways such as hypoxia-inducible factor 1 signal pathway, fatty acid metabolism, and oxidative phosphorylation. A total of 453 targets of Jintiange capsule for treating osteoporosis were identified, including 49 primary core proteins, such as transferrin, ribosomal protein S14, and ribosomal protein S21, and 15 secondary core proteins, such as ribosomal protein S6, ribosomal protein S20, and ribosomal protein S2. These findings indicate that Jintiange capsule may negatively regulate ferroptosis by down-regulating long chain lipoacyl-CoA synthase 1, arachidonic acid-15- lipooxygenase, transferrin, and CREB binding protein to inhibit lipid peroxidation and iron accumulation, thereby modifying osteopenia and trabecular bone microstructure damage in osteoporotic rats.

Key words: Jintiange capsule, osteoporosis, proteomics, retinoic acid, ferroptosis

CLC Number:

Zhang Chi, Zhang Xiaoyun, Chai Yuan, Chen Feng. Proteomic study of Jintiange capsule in the treatment of retinoic acid-induced osteoporosis rats[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(35): 5634-5641.

Figures/Tables 9

References

[1] CUI Z, MENG X, FENG H, et al. Estimation and projection about the standardized prevalence of osteoporosis in (mainland China. Arch Osteoporos. 2019;15(1):2.
[2] 曹志红,丁曼旎,赵彦风.虎产品中医药用史的阶段特征——基于《中华医典》数据库的分析[J]. 自然辩证法通讯,2021,43(7):71-77.
[3] 王鸥,夏维波,成志峰,等.金天格胶囊治疗原发性骨质疏松症的有效性及安全性:随机、双盲双模拟、阳性药平行对照、多中心临床试验[J].中华骨质疏松和骨矿盐疾病杂志,2022,15(2):142-151.
[4] 《中成药治疗优势病种临床应用指南》标准化项目组.中成药治疗骨质疏松症临床应用指南(2021年)[J].中国中西医结合杂志, 2022,42(4):393-404.
[5] YANG Z, YUAN ZZ, MA XL. Network Pharmacology-Based Strategy and Molecular Docking to Explore the (Potential Mechanism of Jintiange Capsule for Treating Osteoporosis. Evid Based Complement Alternat Med. 2021;2021:5338182.
[6] 胡张洁.血清蛋白质组学筛选绝经后骨质疏松生物标志物[D].福州:福建医科大学,2021.
[7] YANG L, HOU A, ZHANG X, et al. TMT-based proteomics analysis to screen potential biomarkers of Achyranthis Bidentatae Radix for osteoporosis in rats. Biomed Chromatogr. 2022;36(4):e5339.
[8] 张建花,沈燚,何玉琼,等.二仙汤抗骨质疏松有效组分对维甲酸致骨丢失大鼠的影响[J].第二军医大学学报,2018,39(2):165-170.
[9] WEN B, ZHOU R, FENG Q, et al. IQuant: an automated pipeline for quantitative proteomics based upon isobaric tags. Proteomics. 2014; 14(20):2280-2285.
[10] SAVITSKI MM, WILHELM M, HAHNE H, et al. A Scalable Approach for Protein False Discovery Rate Estimation in Large Proteomic Data Sets. Mol Cell Proteomics. 2015;14(9):2394-2404.
[11] CHEN C, CHEN H, ZHANG Y, et al. TBtools: An Integrative Toolkit Developed for Interactive Analyses of Big Biological Data. Mol Plant. 2020;13(8):1194-1202.
[12] SHERMAN BT, HAO M, QIU J, et al. DAVID: a web server for functional enrichment analysis and functional annotation (of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216-W221.
[13] KANEHISA M, FURUMICHI M, TANABE M, et al. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017; 45(D1):D353-D361.
[14] SZKLARCZYK D, GABLE AL, NASTOU KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605-D612.
[15] TANG Y, LI M, WANG J, et al. CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems. 2015;127:67-72.
[16] 高世勇,李婉秋,王帅,等.基于网络药理学的小陷胸汤治疗大肠癌的机制研究[J].中草药,2022,53(3):773-782.
[17] 韩昶晓,田向东,朱光宇,等.金天格胶囊对经皮球囊椎体后凸成形术后患者骨密度、骨代谢及生活质量的影响[J].中国骨质疏松杂志,2021,27(1):110-113.
[18] 林若慧,陈赛楠,叶云金,等.基于TMT蛋白质组学分析骨疏康胶囊治疗骨质疏松模型大鼠的机制[J].中国组织工程研究,2021, 25(32):5141-5147.
[19] GASCHLER MM, STOCKWELL BR. Lipid peroxidation in cell death. Biochem Biophys Res Commun. 2017;482(3):419-425.
[20] KAGAN VE, MAO G, QU F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81-90.
[21] DOLL S, PRONETH B, TYURINA YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017; 13(1):91-98.
[22] CHEN P, SONG M, WANG Y, et al. Identification of key genes of human bone marrow stromal cells adipogenesis at an early stage. PeerJ. 2020; 8:e9484.
[23] KLEIN RF, ALLARD J, AVNUR Z, et al. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science. 2004;303(5655):229-232.
[24] JIANG Z, WANG H, QI G, et al. Iron overload-induced ferroptosis of osteoblasts inhibits osteogenesis and promotes osteoporosis: An in vitro and in vivo study. IUBMB Life. 2022;74(11):1052-1069.
[25] WANG Y, LIU Y, LIU J, et al. NEDD4L-mediated LTF protein degradation limits ferroptosis. Biochem Biophys Res Commun. 2020;531(4):581-587.
[26] SHANG N, WU J. Egg White Ovotransferrin Attenuates RANKL-Induced Osteoclastogenesis and Bone Resorption. Nutrients. 2019;11(9):2254.
[27] CHEN X, KANG R, KROEMER G, et al. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280-296.
[28] 贾鹏,邓廉夫.低氧诱导因子-α信号通路与骨形成[J].中华骨科杂志,2015,35(6):676-680.
[29] NI S, YUAN Y, QIAN Z, et al. Hypoxia inhibits RANKL-induced ferritinophagy and protects osteoclasts from (ferroptosis. Free Radic Biol Med. 2021;169:271-282.
[30] WEI J, YANG Y, LU M, et al. Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents. Mini Rev Med Chem. 2018;18(4):296-309.
[31] SEMENZA GL. Pharmacologic Targeting of Hypoxia-Inducible Factors. Annu Rev Pharmacol Toxicol. 2019;59(1):379-403.
[32] BEI J, ZHU S, DU M, et al. Integrative analysis of multiomics data identified acetylation as key variable of (excessive energy metabolism in hyperthyroidism-induced osteoporosis rats. J Proteomics. 2022;252: 104451.